November 9, 2020 Men undergoing active surveillance for prostate cancer have very low rates one percent or less of cancer spread (metastases) or death from prostate cancer, according to a recent study published in The Journal of Urology, an Official Journal of the American Urological Association (AUA). The journal is published in the Lippincott portfolio by Wolters Kluwer.
In the long-term, active surveillance is a safe and viable option for men with low-risk and carefully selected intermediate-risk prostate cancer, according to the report by senior author Peter R. Carroll, MD, MPH, of University of California, San Francisco (UCSF) and colleagues.
During active surveillance, prostate cancer is carefully monitored for signs of progression through regular prostate-specific antigen (PSA) screening, prostate exams, imaging and repeat biopsies. If symptoms develop, or if tests indicate the cancer is more aggressive, active treatment such as surgery or radiation may be warranted.
New data on outcomes of active surveillance
The goal of active surveillance is to avoid or delay the ...